Theralase Partners with University of Toledo in Cancer Research
June 18, 2014 (Source: Accesswire) — Theralase Technologies Inc. (“Theralase”) (TSXV: TLT) (TLTFF: OTC Pink(R)) announced today that it has executed an agreement with the University of Toledo to conduct preclinical research into the safety and effectiveness of Theralase’s Photo Dynamic Compounds (PDCs) in the destruction of bladder cancer in a rat model. The study is entitled, “The use of novel Photo Dynamic Therapy (PDT) in a rat bladder tumor model.”
The first phase of this preclinical study will be to optimize the effectiveness of various Theralase PDCs in the destruction of rat bladder tumor cells (AY-27) using various PDC concentrations and laser light doses.
The second phase will be to complete two in vivo rat tumor model studies. The first set of experiments will examine PDC uptake and distribution in rat bladder tumors. The second set of experiments will focus on destroying rat bladder cancer safely and effectively through the instillation of PDCs into rat bladders exhibiting cancerous tumours and then light activating them.
The outcome of these experiments will provide independent confirmation and optimization of the lead PDC selected for bladder cancer destruction and prove the safety and efficacy of the Theralase lead PDC in the destruction of bladder cancer in a live animal model.
Dr. Arkady Mandel, Chief Scientific Officer at Theralase Inc. stated, “I am interested in reviewing the results of an independent confirmation and optimization of the safety and efficacy of the Theralase PDC in destroying bladder cancer in an orthotopic (occurring at the normal place) rat model. The University of Toledo is a great choice for this research, as their group is well known for expertise in the urological applications of PDT. The results of this preclinical research will allow the Company to progress to Good Manufacturing Practice (GMP) manufacture of the lead PDC. We are delighted to have the experience and knowledge of the University of Toledo on board to execute this pivotal preclinical research, as they will be instrumental in helping us prove the destruction of rat bladder cancer with PDCs in 2014, preparing us for clinical application in 2015.”
Roger Dumoulin-White, President and CEO of Theralase stated that, “Theralase is delighted that we have executed a research agreement with the University of Toledo. Completion of this work is pivotal for Theralase to independently validate and optimize our research findings in the PDT destruction of bladder cancer. Results of the University of Toledo’s work will determine the uptake and distribution of the PDCs into bladder cancer tumors versus healthy bladder and the amount of PDCs required to safely and effectively destroy bladder cancer in a live animal model. This data will be instrumental in helping to determine the proper amount of PDC required for human application. I look forward to reporting on the results of this exciting research later this year.”
About Theralase Technologies Inc.
Theralase Technologies Inc. (“Theralase”) (TSXV: TLT) (TLTFF: OTC Pink(R)) designs, manufactures and markets patented, superpulsed laser technology used in eliminating pain and destroying cancer. Theralase technology is safe and effective in eliminating pain, reducing inflammation and accelerating tissue regeneration in numerous nerve, muscle and joint conditions. Theralase is developing patented Photo Dynamic Compound (PDC) technology that is able to target and destroy cancers, bacteria and viruses when light activated.
This press release contains forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.